These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Moore v. Regents of the University of California: patients, property rights, and public policy. Biagi KG St Louis Univ Law J; 1991; 35(2):433-62. PubMed ID: 16144099 [No Abstract] [Full Text] [Related]
24. The significance of induced pluripotent stem cells for basic research and clinical therapy. Meyer JR J Med Ethics; 2008 Dec; 34(12):849-51. PubMed ID: 19043107 [TBL] [Abstract][Full Text] [Related]
25. Supporting the work of lesser geniuses: an argument for removing obstructions to human embryonic stem cell research. Hazuka CD Univ Miami Law Rev; 2002 Oct; 57(1):157-220. PubMed ID: 15156896 [No Abstract] [Full Text] [Related]
26. Somatic stem cells and tissue engineering shed light on unsolved clinical issues in reproductive medicine: in stem cells we trust. Simón C Fertil Steril; 2012 Jul; 98(1):1-2. PubMed ID: 22658346 [TBL] [Abstract][Full Text] [Related]
28. The inherent ethical challenge of first-in-human pluripotent stem cell trials. Habets MG; van Delden JJ; Bredenoord AL Regen Med; 2014 Jan; 9(1):1-3. PubMed ID: 24350999 [No Abstract] [Full Text] [Related]
29. The use of stem cells in biomedical research. Biotechnology Industry Organization (BIO) position statement. Biotechnology Industry Organization J Biolaw Bus; 1999; 3(1):40-4. PubMed ID: 11933970 [TBL] [Abstract][Full Text] [Related]
31. Stem cells have the potential to rejuvenate regenerative medicine research. Eve DJ; Fillmore R; Borlongan CV; Sanberg PR Med Sci Monit; 2010 Oct; 16(10):RA197-217. PubMed ID: 20885363 [TBL] [Abstract][Full Text] [Related]
32. Intellectual property and patent in stem cell research era. Kiatpongsan S J Med Assoc Thai; 2006 Nov; 89(11):1984-6. PubMed ID: 17205886 [TBL] [Abstract][Full Text] [Related]
33. Chemical control of stem cell fate and developmental potential. Lyssiotis CA; Lairson LL; Boitano AE; Wurdak H; Zhu S; Schultz PG Angew Chem Int Ed Engl; 2011 Jan; 50(1):200-42. PubMed ID: 21184400 [TBL] [Abstract][Full Text] [Related]
34. Stem cell research in Spain: if only they were windmills.. Raya A; Izpisúa Belmonte JC Cell Stem Cell; 2009 Jun; 4(6):483-6. PubMed ID: 19497274 [TBL] [Abstract][Full Text] [Related]
35. Precision manufacturing for clinical-quality regenerative medicines. Williams DJ; Thomas RJ; Hourd PC; Chandra A; Ratcliffe E; Liu Y; Rayment EA; Archer JR Philos Trans A Math Phys Eng Sci; 2012 Aug; 370(1973):3924-49. PubMed ID: 22802496 [TBL] [Abstract][Full Text] [Related]
36. The need for a regen industry voice. Mason C; Dunnill P Regen Med; 2008 Sep; 3(5):621-31. PubMed ID: 18729785 [No Abstract] [Full Text] [Related]
37. Private enterprise and public good: ethical issues in the funding of clinical research. Williams AH; Rowell M Ann R Coll Physicians Surg Can; 1999 Jun; 32(4):227-31. PubMed ID: 12385289 [TBL] [Abstract][Full Text] [Related]
38. How Europe's ethical divide looms over biotech law and patents. Gaskell G; Stares S; Pottage A Nat Biotechnol; 2012 May; 30(5):392-4. PubMed ID: 22565959 [No Abstract] [Full Text] [Related]
39. Commentary: isolated stem cells--patentable as cultural artifacts? Hansson MG; Helgesson G; Wessman R; Jaenisch R Stem Cells; 2007 Jun; 25(6):1507-10. PubMed ID: 17347494 [TBL] [Abstract][Full Text] [Related]
40. Ethical questions to ponder in the European stem cell patent debate. Curley D; Sharples A J Biolaw Bus; 2006; 9(3):12-6. PubMed ID: 17152135 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]